EPT Disclosure

18 May 2006 11:44

Goldman Sachs International18 May 2006 FORM 38.5 DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS (Rule 38.5 of the City Code on Takeovers and Mergers) 1. KEY INFORMATION Name of exempt principal trader Goldman Sachs International Company dealt in CAMBRIDGE ANTIBODY TECHNOLOGY GROUP PLC Class of relevant security to which the Ordinary Sharesdealings being disclosed relate (Note 1) Date of dealing 17 May 2006 2. DEALINGS (Note 2) (a) Purchases and sales Total number of securities purchased Highest price paid (Note 3) Lowest price paid (Note 3) 60000 12.9753 GBP 12.9753 GBP Total number of securities sold Highest price received (Note 3) Lowest price received (Note 3) 57050 12.9756 GBP 12.9756 GBP (b) Derivatives transactions (other than options) Product name, Long/short (Note 4) Number of securities (Note 5) Price per unit (Note 3)e.g. CFD CFD Long 2950 12.9791 GBP (c) Options transactions in respect of existing securities (i) Writing, selling, purchasing or varying Product name, Writing, selling, Number of securities to Exercise Type, e.g. Expiry Option money purchasing, which the option relates American,e.g. call varying etc. (Note 5) price European date paid/received peroption etc. unit (Note 3) (ii) Exercising Product name, e.g. call option Number of securities Exercise price per unit (Note 3) 3. OTHER INFORMATION Agreements, arrangements or understandings relating to options or derivatives Full details of any agreement, arrangement or understanding between the person disclosing and any other person relatingto the voting rights of any relevant securities under any option referred to on this form or relating to the votingrights or future acquisition or disposal of any relevant securities to which any derivative referred to on this form isreferenced. If none, this should be stated. Date of disclosure 18 May 2006 Contact name Peter Highton Telephone number +44-207-774-1935 Name of offeree/offeror with which connected AstraZeneca Nature of connection (Note 6) Advisor Notes The Notes on Form 38.5 can be viewed on the Takeover Panel's website atwww.thetakeoverpanel.org.uk This information is provided by RNS The company news service from the London Stock Exchange